格隆汇9月18日丨迈威生物(688062.SH)公布，2025年9月18日，公司通过集中竞价交易方式首次回购公 司股份135,938股，占公司总股本的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为52.79元/ 股，支付的资金总额为人民币7,361,397.22元（不含印花税、交易佣金等交易费用）。 ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-054 公司于 2025 年 9 月 17 日召开第二届董事会第二十二次会议，审议通过了《关 于调整回购股份价格上限的议案》，同意将回购股份价格上限由人民币 48.00 元/股 （含）调整为人民币 66.46 元/股（含）。具体内容详见公司于 2025 年 9 月 18 日在 上海证券交易所网站（www.sse.com.cn）上披露的《关于调整回购股份价格上限的 公告》（公告编号：2025-053）。除上述调整外，回购股份方案的其他内容不变。 二、 首次实施回购股份的情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司首次实施回购股份情况公告如下： 迈威（上海）生物科技股份有限公司 关于以集中竞价交易方式首次回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/27 | | --- | --- | | 回购方案实施期限 | 年 月 日~ ...

智通财经APP讯，迈威生物(688062.SH)发布公告，2025年9月18日，公司通过集中竞价交易方式首次回 购公司股份135,938股，占公司总股本的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为 52.79元/股，支付的资金总额为人民币736.14万元。 ...

迈威生物(688062.SH)发布公告，2025年9月18日，公司通过集中竞价交易方式首次回购公司股份135,938 股，占公司总股本的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为52.79元/股，支付的资 金总额为人民币736.14万元。 ...

迈威生物公告，2025年9月18日，公司通过集中竞价交易方式首次回购公司股份135,938股，占公司总股 本399,600,000股的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为52.79元/股，支付的资金 总额为人民币7,361,397.22元（不含印花税、交易佣金等交易费用）。本次回购股份符合相关法律法规 及公司回购股份方案的规定。 ...

Core Viewpoint - The A-share market is experiencing a slight decline, with the Shanghai Composite Index closing at 3852.23 points, down 0.62% and below the five-day moving average, while the total trading volume reached 23,670.80 billion yuan [1]. Group 1: Market Performance - As of the latest data, 328 A-shares have surpassed the five-day moving average, indicating a mixed performance in the market [1]. - The total trading volume in the A-share market today is reported at 23,670.80 billion yuan [1]. Group 2: Individual Stock Performance - The stocks with the highest deviation from the five-day moving average include: - 德众汽车 (Dazhong Automobile) with a deviation rate of 22.13%, experiencing a daily increase of 30.00% and a turnover rate of 30.84% [2]. - 福事特 (Fushite) with a deviation rate of 13.88%, increasing by 18.86% today with a turnover rate of 22.61% [2]. - 亿华通 (Yihua Tong) showing a deviation rate of 10.10%, up by 13.75% with a turnover rate of 13.36% [2]. - Other notable stocks with significant performance include: - 沃尔德 (World) with a deviation rate of 8.54% and a daily increase of 14.82% [2]. - 兴业科技 (Xingye Technology) with a deviation rate of 8.27% and a daily increase of 10.01% [2].

Market Overview - The Shanghai Composite Index is at 3894.62 points, above the five-day moving average, with an increase of 0.47% [1] - The total trading volume of A-shares is 12,225.01 billion yuan [1] Stocks Performance - A total of 591 A-shares have surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Dezhong Automobile: 22.13% deviation, with a price increase of 30.00% [1] - Xingye Technology: 8.27% deviation, with a price increase of 10.01% [1] - Hanzhong Precision: 8.11% deviation, with a price increase of 9.99% [1] - Other stocks with smaller deviation rates include Tongrentang, China Satellite, and Hengyu Environmental Protection, which have just crossed the five-day moving average [1] Detailed Stock Data - The report includes a detailed table of stocks that broke the five-day moving average on September 18, with their respective trading performance, turnover rates, and deviation rates [1][2]

消息面上，迈威生物发布公告称，公司与Kalexo Bio, Inc.公司（以下简称"Kalexo"）就2MW7141项目相 关签署《独家许可协议》及《优先股股权购买协议》。根据许可协议和股权购买协议，迈威生物许可 Kalexo就2MW7141项目相关在全球范围的独家开发、生产和商业化以及其他方式开发许可产品的权 利。迈威生物将从Kalexo获得最高可达10亿美元的预付款和里程碑付款，以及低个位数的特许权使用 费，其中包括一次性、不可返还的首付款及近端付款1200万美元现金，作为对价的一部分，迈威生物将 在符合约定条件下另外获得Kalexo总计双位数的A轮优先股。 北京商报讯（记者 丁宁）9月18日，迈威生物（688062）以涨停开盘，开盘报58.03元/股，涨幅为 20%。 ...

迈威生物20cm一字涨停，公司与Kalexo签署独家许可协议，最高可获10亿美元预付款和里程碑付款。 ...

Policy Developments - The head of the National Medical Products Administration emphasized the importance of improving the efficiency of drug review and approval processes to ensure product quality and accelerate the market entry of new drugs [2] - Measures include prioritizing the review of urgently needed clinical products, reducing the review time for innovative drug clinical trials from 60 to 30 working days, and optimizing supplementary application review procedures [2] Industry Insights - The optimization of the review and approval process addresses the issues of "difficult and expensive medication" for patients, while also reducing time and institutional transaction costs for pharmaceutical companies, alleviating core pressures in R&D, production, and operations [3] Market Developments - Health 160 successfully listed on the Hong Kong Stock Exchange, closing at HKD 28.22 per share, with a market capitalization of HKD 9.495 billion [10] - Meikang Bio's subsidiary obtained a medical device registration certificate for four products, enhancing the company's product line and market competitiveness [7] Innovation and Drug Approvals - In the first seven months of the year, 50 innovative drugs were approved, surpassing the total of 48 for the entire previous year, indicating a strong momentum in drug innovation [13] - The approval of innovative drugs is driven by policy support, technological advancements, and increased capital investment, with a shift from me-too drugs to first-in-class innovations [13] Strategic Partnerships - Maiwei Bio signed an exclusive licensing agreement with Kalexo Bio, potentially receiving up to USD 1 billion in upfront and milestone payments, which is expected to positively impact the company's future performance [14]